SCHEMBL334462

SCHEMBL334462

O=C(O)N1CCC2CNCCC21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A1 P30531 4/20 0.36
GABRA5 P31644 3/20 0.36
GABRB2 P47870 3/20 0.36
SLC6A11 P48066 3/20 0.36
SLC6A13 Q9NSD5 3/20 0.36
SLC6A12 P48065 2/20 0.36
GABRA1 P14867 2/20 0.36
GABRA4 P48169 2/20 0.36
GABRR1 P24046 1/20 0.36
TSHR P16473 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRE P78334 1/20 0.33
PMP22 Q01453 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18692612 1.00 SLC6A1 (0.36) SLC6A1GABRA5GABRB2SLC6A11SLC6A13
SCHEMBL20744258 1.00 SLC6A1 (0.36) SLC6A1GABRA5GABRB2SLC6A11SLC6A13
SCHEMBL1470518 0.85 SLC6A1 (0.36) SLC6A1GABRA5GABRB2SLC6A11SLC6A13
SCHEMBL20744262 0.85 SLC6A1 (0.36) SLC6A1GABRA5GABRB2SLC6A11SLC6A13
SCHEMBL20136819 0.85 SLC6A1 (0.36) SLC6A1GABRA5GABRB2SLC6A11SLC6A13
SCHEMBL27198371 0.85 SLC6A1 (0.36) SLC6A1GABRA5GABRB2SLC6A11SLC6A13
SCHEMBL3579211 0.85 PARP1 (0.38) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL1033901 0.85 PARP1 (0.38) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL3582591 0.85 PARP1 (0.38) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL3816058 0.83 SLC6A1 (0.37) SLC6A1GABRA5GABRB2SLC6A11SLC6A13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119677726-A KRAS inhibitors 百时美施贵宝公司 2025-03-21 CN disclosed
CN-112939967-B Pyrazolo [1,5-a ] pyridine compound, and preparation method and application thereof 深圳众格生物科技有限公司 2024-08-27 CN disclosed
CN-114787161-B Pyrazolo [1,5-a ] pyridine compound, and preparation method and application thereof 深圳众格生物科技有限公司 2024-08-02 CN disclosed
CN-114787161-A Pyrazolo [1,5-a ] pyridine compound and preparation method and application thereof 深圳众格生物科技有限公司 2022-07-22 CN disclosed
WO-2021115457-A9 PYRAZOLO[1,5-A]PYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 深圳众格生物科技有限公司 2022-05-19 WO disclosed
US-20180028508-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RES INC (US) 2018-02-01 US disclosed
US-20170101405-A1 N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE ABBVIE S.Á.R.L. (LU) 2017-04-13 US disclosed
US-20160304516-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Quanticel Pharmaceuticals, Inc. 2016-10-20 US disclosed
EP-2780342-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE Sunshine Lake Pharma Co., Ltd. (CN) 2014-09-24 EP disclosed
CN-101868464-B Thienopyrimidiene derivatives as PI3k inhibitors HOFFMANN LA ROCHE 2013-11-13 CN disclosed
WO-2013071697-A1 AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2013-05-23 WO disclosed
US-8097626-B2 IL-8 receptor antagonists GLAXOSMITHKLINE LLC (US) 2012-01-17 US disclosed
CN-101868464-A Thienopyrimidiene derivatives as PI3k inhibitors HOFFMANN LA ROCHE 2010-10-20 CN disclosed
US-20090298810-A1 IL-8 Receptor Antagonists SMITHKLINE BEECHAM CORPORATION 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170101405-A1 N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE CFTR, P2RY1, P2RX5 SLC6A1 2828/4885GABRA5 2261/4885GABRB2 2679/4885
US-20180028508-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A SLC6A1 4080/4885GABRA5 2666/4885GABRB2 2155/4885
US-20090298810-A1 IL-8 Receptor Antagonists CXCL8, CCR8, IL1RN SLC6A1 3880/4885GABRA5 544/4885GABRB2 656/4885
US-20160304516-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A SLC6A1 4080/4885GABRA5 2666/4885GABRB2 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.